Robert Dunne

GlycoSeLect Ltd Featured in the Irish Times

GlycoSeLect Ltd was recently featured in an Irish Times article about new innovators.

“At first glance, glycoproteins may not seem to have much relevance for everyday life, but they are in fact the bedrock of the biopharmaceutical industry and are used in the food and cosmetics sectors.

The problem with glycoproteins is that they are difficult to analyse, so anything that simplifies the process is of big interest to the multimillion dollar turnover industries involved.

Currently making waves in the glycoproteins pool is Dublin City University life-sciences spin-out GlycoSeLect. Set up in 2013, its disruptive technology can make glycoprotein analysis and manufacturing cheaper and more effective.”

About GlycoSelect Ltd

GlycoSeLect Ltd develops innovative technologies for the analysis, characterisation and purification of biopharmaceuticals. These next-generation products are highly specific for glycan structures improving product development and improving the cost-efficiency of their manufacturing. GlycoSeLect specialises in the development of proteins based on recombinant prokaryotic lectins RPLs. Our RPL products advance efficient detection, analysis and selective isolation of glycosylated pharmaceutical products. GlycoSeLect’s family of RPLs products are associated with market-leading properties, including high affinity for glycan targets, high sensitivity of detection, high stability and robustness in process development.

More Stories